<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129086</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-19-0726</org_study_id>
    <nct_id>NCT04129086</nct_id>
  </id_info>
  <brief_title>Ketamine for Acute Pain Management After Trauma</brief_title>
  <acronym>KAPT</acronym>
  <official_title>Ketamine for Acute Pain After Trauma: KAPT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of Ketamine drip along with usual
      care and usual care alone on trauma patients and to longitudinally quantify the pain
      experience of patients during hospitalization.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average daily opioid use as measured by the Morphine Milligram Equivalents per day</measure>
    <time_frame>In-hospital days (up to 6 weeks post hospital admission)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-hospital pain scores</measure>
    <time_frame>Hospital discharge(up to 6 weeks post hospital admission)</time_frame>
    <description>Daily pain scores on a numeric scale from 0 - 10 during in-hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that showed signs of delirium during in-hospital stay</measure>
    <time_frame>Hospital discharge(up to 6 weeks post hospital admission)</time_frame>
    <description>Incidence of delirium during in-hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that required unplanned intubation during in-hospital stay</measure>
    <time_frame>Hospital discharge(up to 6 weeks post hospital admission)</time_frame>
    <description>incidence of need for unplanned intubation during in-hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who required unplanned admission to intensive care unit during in-hospital stay</measure>
    <time_frame>Hospital discharge(up to 6 weeks post hospital admission)</time_frame>
    <description>Incidence of need for unplanned admission to an ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation of Ketamine drip</measure>
    <time_frame>Hospital discharge(up to 6 weeks post hospital admission)</time_frame>
    <description>Time from admission to time Ketamine drip started</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Ketamine drip</measure>
    <time_frame>Hospital discharge(up to 6 weeks post hospital admission)</time_frame>
    <description>Length of time Ketamine drip was infused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requesting to discontinue Ketamine</measure>
    <time_frame>Hospital discharge(up to 6 weeks post hospital admission)</time_frame>
    <description>Number of patients requesting to stop Ketamine for any complaint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of other pain control adjuncts including regional anesthesia and lidocaine patch</measure>
    <time_frame>Hospital discharge(up to 6 weeks post hospital admission)</time_frame>
    <description>Incidence of use of additional pain control adjuncts such as regional anesthesia and lidocaine patch during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>Hospital discharge(up to 6 weeks post hospital admission)</time_frame>
    <description>Number of inpatient hospital days patients did not require mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU free days</measure>
    <time_frame>Hospital discharge(up to 6 weeks post hospital admission)</time_frame>
    <description>Number of inpatient hospital days patients did not require ICU level of care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital free days</measure>
    <time_frame>30 days post admission</time_frame>
    <description>Number of days patients were not in the hospital during the first 30 days after admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge from hospital with opioid prescription</measure>
    <time_frame>Hospital discharge(up to 6 weeks post hospital admission)</time_frame>
    <description>Number of patients discharged from the hospital with an opioid prescription</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status at hospital discharge</measure>
    <time_frame>Hospital discharge (about 1 to 6 weeks)</time_frame>
    <description>Health status measured by the patients' answers to the EuroQol-5D-5L questionnaire which is based in a scale from 0 - 100 with higher scores indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status 6 months post admission</measure>
    <time_frame>6 months post admission</time_frame>
    <description>Health status measured by the patients' answers to the EuroQol-5D-5L questionnaire which is based in a scale from 0 - 100 with higher scores indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of continued post-traumatic pain at 6 months post admission</measure>
    <time_frame>6 months post admission</time_frame>
    <description>Number of patients who reported continued pain at 6 months following trauma injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent opioid use at 6 months post admission</measure>
    <time_frame>6 months post admission</time_frame>
    <description>Number of patients who continue to use opioids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post traumatic Stress Disorder (PTSD) screening measured by patients' answers to the PC-PTSD-5 questionnaire at 6 months.</measure>
    <time_frame>6 months post admission</time_frame>
    <description>Post traumatic screening status measured by the patients' answers to the PC-PTSD-5.
The questionnaire is measured on a scale from 0-5 higher the score the more likely to be prone to PTSD.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Trauma Injury</condition>
  <condition>Pain</condition>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Ketamine plus Usual care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine plus usual care</intervention_name>
    <description>Bolus of .35 mg/kg Infusion start @ 0.15 mg/kg/hr; titrate range is 0.1 - 0.25 mg/kg/hr for 24 to 48 hours after admission and each subsequent major surgery plus multi-modal pain therapy considered as standard of care. Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.</description>
    <arm_group_label>Ketamine plus Usual care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult trauma patients

          -  Admission to Shock Trauma ICU (STICU) or Surgical Intermediate Unit (SIMU)

          -  Randomization within 6 hours of arrival

        Exclusion Criteria:

          -  Patient not expected to survive

          -  Contraindications to ketamine Allergy, Poorly controlled hypertension, Cardiac
             arrhythmia disorders (including atrial fibrillation), congestive heart failure,
             unstable coronary artery disease or recent myocardial infarction( MI)(within 6
             months), cirrhosis, seizure disorder, and for those patients with unknown medical
             history - median sternotomy scar, mechanism of injury is fall from standing, 65 years
             of age or older, any arrhythmia on EKD)

          -  pregnancy

          -  in police custody

          -  history of dementia or movement disorder (i.e. Parkinson's)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Harvin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Harvin, MD</last_name>
    <phone>713500-7200</phone>
    <email>John.Harvin@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeanette Podbielski, RN</last_name>
    <phone>713-500-6407</phone>
    <email>Jeanette.M.Podbielski@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>John Harvin, MD</last_name>
      <phone>713-500-7292</phone>
      <email>John.Harvin@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeanette Podbielski, RN</last_name>
      <phone>713-500-6407</phone>
      <email>Jeanette.Podbielski@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Harvin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>John Andrew Harvin</investigator_full_name>
    <investigator_title>Associate Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Multimodal Pain Therapy</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Trauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

